{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:11Z","timestamp":1793061311599,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430093"],"award-info":[{"award-number":["82430093"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577050"],"award-info":[{"award-number":["22577050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22322703"],"award-info":[{"award-number":["22322703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102948","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:40:42Z","timestamp":1785336042000},"page":"102948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["An antibody-PROTAC conjugate targets BRD4\/c-Myc\/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5860-5588","authenticated-orcid":false,"given":"Yunru","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-0046","authenticated-orcid":false,"given":"Xiaoxiang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102948_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102948_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib3","first-page":"159","article-title":"FDA approves TROP2-targeted antibody-drug conjugate for breast cancer","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102948_bib4","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-23-0583","article-title":"Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence","volume":"30","author":"Vaidya","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102948_bib5","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102948_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials","volume":"18","author":"Tan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102948_bib13","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425812122","article-title":"Discovery of an LSD1 PROTAC degrader","volume":"122","author":"Hosseini","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102948_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/0008-5472.CAN-24-1093","article-title":"Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia","volume":"85","author":"Luo","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102948_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102948_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117159","article-title":"Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines","volume":"241","author":"Hu","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102948_bib17","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102948_bib18","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer","volume":"145","author":"Li","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.102948_bib19","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.xcrm.2026.102948_bib20","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: A safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102948_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102948_bib22","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.xcrm.2026.102948_bib23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/thno.102531","article-title":"A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2026.102948_bib24","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.jmedchem.0c01845","article-title":"Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties","volume":"64","author":"Dragovich","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102948_bib25","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","article-title":"Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy","volume":"64","author":"Dragovich","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102948_bib26","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2026.102948_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102948_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib29","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib31","doi-asserted-by":"crossref","first-page":"46626","DOI":"10.1021\/acsami.9b18730","article-title":"JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC\/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer","volume":"11","author":"Tian","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.xcrm.2026.102948_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112034","article-title":"BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer","volume":"392","author":"Jing","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.xcrm.2026.102948_bib33","article-title":"Enzyme-Activated Orthogonal Proteolysis Chimeras for Tumor Microenvironment-Responsive Immunomodulation","volume":"64","author":"Sun","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xcrm.2026.102948_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102948_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102948_bib36","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102948_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102948_bib38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2022.03.041","article-title":"Triggered azobenzene-based prodrugs and drug delivery systems","volume":"345","author":"Zhu","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.xcrm.2026.102948_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202310318","article-title":"Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates","volume":"63","author":"Xiao","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.xcrm.2026.102948_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41571-025-01054-6","article-title":"Therapeutic targeting of mismatch repair-deficient cancers","volume":"22","author":"Johannet","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102948_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102948_bib43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-24-2589","article-title":"Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes","volume":"85","author":"Sawant","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102948_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102948_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70484","article-title":"Targeting c-Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple-negative breast cancer","volume":"15","author":"Liang","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102948_bib46","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s11427-023-2433-y","article-title":"Ultrasound-responsive spherical nucleic acid against c-Myc\/PD-L1 to enhance anti-tumoral macrophages in triple-negative breast cancer progression","volume":"67","author":"Wang","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.xcrm.2026.102948_bib47","doi-asserted-by":"crossref","first-page":"21417","DOI":"10.1021\/acsnano.2c09788","article-title":"Two-Stage SN38 Release from a Core-Shell Nanoparticle Enhances Tumor Deposition and Antitumor Efficacy for Synergistic Combination with Immune Checkpoint Blockade","volume":"16","author":"Jiang","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.xcrm.2026.102948_bib48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2326-6066.CIR-21-0826","article-title":"Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer","volume":"10","author":"Lee","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102948_bib49","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1038\/s41467-022-34000-6","article-title":"MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling","volume":"13","author":"Zimmerli","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102948_bib50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ccell.2025.05.014","article-title":"Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models","volume":"43","author":"Vitiello","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102948_bib51","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102948_bib52","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102948_bib53","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102948_bib54","doi-asserted-by":"crossref","first-page":"19971","DOI":"10.1021\/acs.jmedchem.5c00492","article-title":"Novel Aptamer-Drug Conjugate for Targeted Therapy in Triple-Negative Breast Cancer","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102948_bib55","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.apsb.2024.03.012","article-title":"Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer","volume":"14","author":"Gao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.102948_bib56","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1021\/jacs.4c18398","article-title":"A Dual-Targeted Molecule for Disease-Activatable Proteolysis Targeting Chimeras and Targeted Radionuclide Therapy of Cancer","volume":"147","author":"Zhang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.102948_bib57","article-title":"A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines","volume":"31","author":"Huang","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.xcrm.2026.102948_bib58","article-title":"Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.xcrm.2026.102948_bib59","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.1021\/acs.nanolett.4c02287","article-title":"Ultrasound-Activated PROTAC Prodrugs Overcome Immunosuppression to Actuate Efficient Deep-Tissue Sono-Immunotherapy in Orthotopic Pancreatic Tumor Mouse Models","volume":"24","author":"Liu","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.xcrm.2026.102948_bib60","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1021\/jacs.3c04109","article-title":"Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy","volume":"145","author":"Wang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.102948_bib61","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"Antitumor Effect of Anti-c-Myc Aptamer-Based PROTAC for Degradation of the c-Myc Protein","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2026.102948_bib62","doi-asserted-by":"crossref","first-page":"14155","DOI":"10.1021\/jacs.3c05159","article-title":"Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation","volume":"145","author":"Chang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.102948_bib63","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.xcrm.2026.102948_bib64","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102948_bib65","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer-the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102948_bib66","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS(G12D)","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102948_bib67","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","article-title":"Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102948_bib68","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1021\/jacs.5c00131","article-title":"Dual-Action-Only PROTACs","volume":"147","author":"Dutta","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.102948_bib69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102948_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202510641","article-title":"Tandem-Activatable PROTAC Prodrug for Tumor Biomarker-Driven Near-Infrared Opto-Proteolysis","volume":"64","author":"Lu","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.xcrm.2026.102948_bib71","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41565-023-01533-w","article-title":"A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering","volume":"19","author":"Krishnan","year":"2024","journal-title":"Nat. Nanotechnol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:24:57Z","timestamp":1793060697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003654"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102948","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An antibody-PROTAC conjugate targets BRD4\/c-Myc\/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102948"}}